Special Issue

Oncologic Thermoradiotherapy: Need for Evidence, Harmonisation, and Innovation

Message from the Guest Editors

In this issue, the focus is on demonstrating the benefits of thermoradiotherapy as an ideal combined oncologic treatment modality to improve clinical outcome. In addition, the issue reports progress in soft and hard tools to guide thermal dose control and improve smooth integration of thermotherapy in the radiotherapy clinical workflow. We hope the contributions will further substantiate clinical acceptance following earlier published randomised clinical trials and meta-analysis as well as strengthen acceptance of thermotherapy by patients, patient organisations, primary care medical staff, medical specialists, and oncologists.

Guest Editors

Prof. Dr. Stephan Bodis

Prof. Dr. Pirus Ghadjar

Prof. Dr. Gerard C. Van Rhoon

Deadline for manuscript submissions

closed (31 January 2022)



Cancers

an Open Access Journal by MDPI

Impact Factor 4.5 CiteScore 8.0 Indexed in PubMed



mdpi.com/si/87409

Cancers
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/ cancers





Cancers

an Open Access Journal by MDPI

Impact Factor 4.5 CiteScore 8.0 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, LISA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

